Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs.
McKoy JM, Lyons EA, Obadina E, Carson K, Pickard AS, Schellhammer P, McLeod D, Boyd CE, McWilliams N, Sartor O, Schumock GT, McCaffery K, Bennett CL.
J Clin Oncol. 2005 Dec 1;23(34):8894-905. Review.PMID: 16314650 [PubMed - indexed for MEDLINE]Related articles